5,6,7,8-四氢吖啶-4-胺 | 3198-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5,6,7,8-四氢吖啶-4-胺
• 英文名称: 1,2,3,4-Tetrahydro-5-aminoacridine
• 英文别名: 5,6,7,8-tetrahydroacridin-4-amine
• CAS: 3198-41-2
• 化学式: C₁₃H₁₄N₂
• 分子量: 198.26
• InChiKey: MOWGHIVIVXUXBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE, PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT
  申请人：MITHRIDION INC

  公开号：WO2010102218A1

  公开（公告）日：2010-09-10

  Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

  提供了用于刺激肌气受体并治疗认知障碍的肌气受体激动剂。还提供了合成这类激动剂的方法。还提供了用于增强人类等受试者认知功能的组合物，该组合物包括肌气受体激动剂或其药用适宜形式。还提供了通过给予这类组合物来治疗动物如人类的方法。
• Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating
  申请人：Mithridion, Inc.

  公开号：US20130274299A1

  公开（公告）日：2013-10-17

  The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

  本发明涉及肌肉碱受体激动剂，其可用于刺激肌肉碱受体和治疗认知障碍。本文所披露的肌肉碱受体激动剂包括噁唑烷衍生物、组合物及其制备。还提供了合成噁唑烷化合物的方法。本公开还涉及用于增强人类等受试者认知功能的组合物，该组合物包括肌肉碱受体激动剂或其药学适宜形式。本公开还涉及通过给予该类组合物治疗动物，如人类的方法。
• Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating
  申请人：NeuroSolis, Inc.

  公开号：US20150099765A1

  公开（公告）日：2015-04-09

  Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

  本发明涉及包括噁唑烷衍生物在内的毒蕈碱受体激动剂化合物，以及其组合物和制备方法。本发明还涉及合成这种噁唑烷化合物的方法。本发明还涉及使用所述毒蕈碱受体激动剂或其药学适宜形式来增强认知功能的方法。
• Pharmaceutical composition for the treatment of underlying nonpharmacologically induced nervous system cholinergic deficit state comprising monoamine acridine derivatives
  申请人：Summers, William Koopmans

  公开号：EP0595365A1

  公开（公告）日：1994-05-04

  A pharmaceutical composition for treatment of underlying nonpharmacologically induced central or peripheral nervous system cholinergic deficit state in humans comprising a monoamine acridine derivative of the formula: wherein R₁ represents hydrogen, hydroxy, methyl, methoxy, ethyl or ethoxy; R₁ and R₂ together may form a double bond, R₃ and R₄ together may form a double bond, or R₁, R₂, R₃ and R₄ are all hydrogen; R₅ represents hydrogen, hydroxy, methoxy or ethoxy; R₆ represents hydrogen, hydroxy, methoxy or ethoxy; and R₇ is without a substituent or R₇ represents an oxygen atom, a C₁-C₂₀ alkyl radical or a radical selected from the group consisting of    -R-N(R)₂, wherein each R is independently selected from C₁-C₂₀ alkyl; or a pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable inert carrier therefor; with the provisos that the monoamine acridine derivative is a compound in which (i) if R₁, R₂, R₃, R₄, R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, (ii) if R₁ and R₂ together form a double bond, R₃ and R₄ together form a double bond and R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, and (iii) if R₃ and R₄ together form a double bond and R₇ is without a substituent, then R₁ cannot be a hydrogen atom is provided.

  一种用于治疗非药物诱导的人体中枢或外周神经系统胆碱能缺失状态的药物组合物，包含一种式的单胺吖啶衍生物： 其中 R₁ 代表氢、羟基、甲基、甲氧基、乙基或乙氧基；R₁ 和 R₂ 一起可形成双键，R₃ 和 R₄ 一起可形成双键，或 R₁、R₂、R₃ 和 R₄ 均为氢；R₅ 代表氢、羟基、甲氧基或乙氧基； R₆ 代表氢、羟基、甲氧基或乙氧基；且 R₇ 不含取代基，或 R₇ 代表氧原子、C₁-C₂₀ 烷基或选自以下组别的基团 -R-N(R)₂、 其中每个 R 独立地选自 C₁-C₂₀ 烷基；或其药学上可接受的盐，以及药学上可接受的惰性载体；但条件是，单胺吖啶衍生物是一种化合物，其中 (i) 如果 R₁、R₂、R₃、R₄、R₅ 和 R₆ 各为氢，则 R₇ 不能没有取代基，(ii) 如果 R₁ 和 R₂ 一起形成双键、R₃ 和 R₄ 共同形成双键，且 R₅ 和 R₆ 各为氢原子，则 R₇ 不能不含取代基，以及 (iii) 如果 R₃ 和 R₄ 共同形成双键，且 R₇ 不含取代基，则 R₁ 不能为氢原子。
• Novel herbal formulation as brain tonic
  申请人：Pushpangadan Palpu

  公开号：US20050142232A1

  公开（公告）日：2005-06-30

  The invention provides a novel herbal formulation used to improve the memory and in treatment of amnesia as a brain tonic. Formulation(s) comprises of oleaginous oil of Sesamum indicum and the alcoholic extract of Centella asiatica . Conventionally used as emulsion or as a soft gelatin capsule for oral dosage forms. Sesamum indicum used in paralysis, aphrodisiac and dysmenorrhoea. The plant of Centella asiatica is considered as a useful alternative and tonic in diseases of the skin, nerves and blood.

  本发明提供了一种新型草药配方，用于改善记忆力和治疗健忘症，是一种补脑药物。配方由以下成分组成 芝麻 和 积雪草 .通常用作口服剂型的乳剂或软明胶胶囊。 芝麻 用于麻痹、壮阳和痛经。积雪草 积雪草 被认为是皮肤、神经和血液疾病的有效替代品和滋补品。